Dianthus Therapeutics, Inc. - Common Stock DNTH 深 沪
已收盘 12-19 16:00:00 美东时间
42.47
+0.720
+1.72%
华盛通- 最 高45.455
- 今 开41.74
- 成交量 80.66万股
- 最 低 40.16
- 昨 收 41.75
- 总市值 0
- 52周最高 45.455
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 13.365
- 委 比 -92.34%
- 总股本 --
- 历史最高 45.455
- 量 比 1.46
- 振 幅 12.68%
- 历史最低 0.321
- 每 手 1
- 风险率 8.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【晨观方正】创新药多个BD落地映证产业趋势持续 / 香港楼市是怎样止跌回稳的？20251021
今天是2025年10月21日星期二，农历八月二十九。每一个秋日的清晨，方正研究向您提供及时新鲜的研究观点，秉持“独立、客观、理性、真诚”的理念，珍重您的信任，保...
10-21 08:33
一天三个BD，创新药再掀狂潮！翰森制药逆市涨近4%，BD总额超15.3亿美元！港股通创新药ETF(159570)资金近20日净流入超29亿元！
今日（10.17），在连续两日反攻后，港股通创新药ETF（159570）回调一度超1%，现跌幅收窄至0.38%，盘中成交额快速突破8.6亿元！资金面上，近20日...
10-17 11:18
10亿美元出海，来自今年最火IPO之一
（来源：动脉新医药） 10月16日晚，南京维立志博与Dianthus Therapeutics宣布已就DNTH212（LBL-047）达成独家许可协议。双方达成...
10-17 08:00
维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议
维立志博-B(09887)发布公告，于2025年10月16日，本公司与Dianthus Therapeutics, Inc.(Dianthus，纳斯达克代码：...
10-16 20:55
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
Dianthus Therapeutics announced its participation in the Jefferies Global Healthcare Conference, with CEO Marino Garcia to hold a fireside chat and investor meetings. The company focuses on developing advanced antibody therapies for severe autoimmune diseases.
05-29 11:00
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dianthus Therapeutics appoints Simon Read, Ph.D., to its Board of Directors, while Lonnie Moulder steps down. Dr. Read, a seasoned biopharmaceutical leader with over 30 years of experience, previously founded and led Mariana Oncology and Ra Pharma. Dianthus is advancing innovative antibody complement therapeutics for severe autoimmune diseases, with three clinical programs underway, including DNTH103.
05-22 20:10
Dianthus Therapeutics Q4 EPS $(0.81) Beats $(0.85) Estimate, Sales $1.32M Beat $859.70K Estimate
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 14.08 percent decrease over losses of $(0.71) per share
03-12 04:03
Expert Ratings For Dianthus Therapeutics
Throughout the last three months, 4 analysts have evaluated Dianthus Therapeuti...
2024-09-26 20:00
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $40 price target.
2024-09-26 18:38
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Friday. Shares of Ulta Beauty, Inc. (NASDAQ:ULTA) fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its second quarter and cut its FY24 guidance. Ult...
2024-08-30 20:29
